Which Peptides Has Andrew Huberman Said He Uses?

Every few months a clip resurfaces of Andrew Huberman naming a peptide he has tried, and within a day the internet has converted his hedged, personal anecdote into a “nightly protocol” with specific microgram figures. The names that recur are pinealon, BPC-157 and sermorelin. Two things are true at once here, and keeping them apart is the whole point of this page: what a public figure says he personally did is a documented statement, and what the primary literature shows about those molecules is a separate question with a much less flattering answer. Everything below describes laboratory and literature findings, plus fair-comment on on-record public statements — not use in people, and not a protocol.

What did he actually say he uses?

Three peptides come up as stated personal use, and they are not equal in either confidence or evidence. Pinealon is the current one, discussed in the context of sleep and REM. BPC-157 is a past use he has tied to a specific injury. Sermorelin is one he has said he tried and then stopped. A fourth, epithalon, gets discussed as a topic but is not something he has claimed to take. And several peptides that float around “Huberman peptide stack” listicles — Semax for focus, ipamorelin as a “top pick,” MK-677 — are either not his stated personal use or lack a locatable primary-source quote. We treat those as internet extras, not his words.

One editorial caveat we will not hide: the specific episode and event claims behind these quotes — a 2026 Huberman Lab conversation, a discussion with Dr. Craig Koniver, a talk at a health event — sit outside PubMed and were not independently verified in the scientific record. They should be checked against the actual recording or transcript before anyone treats a given sentence as an exact quote. What follows attributes the personal-use claims to Huberman with his own hedges intact, and then does the thing the clips never do: read the underlying science honestly. For a deeper claim-by-claim breakdown, see our companion piece, the Huberman peptides fact-check.

Pinealon: a striking anecdote on a single-lineage literature

Pinealon is a synthetic tripeptide, glutamate–aspartate–arginine (Glu-Asp-Arg), also written EDR. It belongs to a family the originating group calls “short” or “ultrashort” peptides. The core primary paper that names pinealon explicitly and reports its effects — dose-dependent suppression of reactive oxygen species and reduced necrotic death in neuronal and PC12 cells — is a Khavinson-group study in cultured cells¹. A later review confirms the pinealon = EDR = Glu-Asp-Arg identity and lays out the proposed mechanism². For the naming trap, see what pinealon actually is: despite the “pineal” root, it is not the pineal peptide. That distinction belongs to epithalon (AEDG).

The proposed mechanism is more ambitious than a simple antioxidant story. In the reviews, the tripeptide is described as entering cells, reaching the nucleus, binding histones and DNA, and modulating transcription — touching MAPK/ERK signalling, caspase-3 and p53, the antioxidant enzymes SOD2 and GPX1, and serotonin pathways². This is the “neuroepigenetic ultrashort peptide” hypothesis³. The one experiment people point to for the nuclear-binding step showed short fluorescence-labelled peptides penetrating the nucleus in HeLa cells and binding DNA in a cell-free assay⁵ — real data, but in a cervical-cancer cell line and on naked DNA, not in a living brain. The most current primary work extends the neuroprotection findings to fibroblast-derived induced human neurons⁴; still cell culture, still the same lineage. In-vivo pinealon work is thin, and what exists is in unrelated injury models — for example a rat prenatal-hyperhomocysteinemia study, published in a now-defunct low-tier journal⁶.

0 published randomized controlled trials in humans test pinealon for sleep or REM.

So the honest version of the pinealon story is this: a genuinely interesting n=1 anecdote from a well-known scientist, resting on a preclinical literature that is real but originates almost entirely from one research program, with no independent Western replication and no controlled human trial for the outcome he described. The corrected framing on the personal-use side matters too — the widely repeated “every night” is an overstatement; his own account is closer to occasional use, a few times a month, as an experiment.

A striking personal anecdote is not a controlled trial, and a single-lab literature is not independent evidence.

BPC-157: broad animal data, three human pilots

BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — originally derived from a fragment of a human gastric-juice protein. Its animal mechanism story is comparatively rich: VEGFR2 activation, the Akt–eNOS nitric-oxide axis, ERK1/2 signalling, angiogenesis and fibroblast activity⁷. There is even some replication beyond the original Zagreb group — an independent Taiwan team reported tendon fibroblast outgrowth and migration in vitro and in rats⁹. Our primer on what BPC-157 is covers the chemistry in more depth.

The human column is nearly empty. A December-2025 narrative review found that human data are extremely limited — only three human pilot studies exist in total: one on intra-articular knee pain, one on interstitial cystitis, and one on intravenous pharmacokinetics and safety⁷. There is no efficacy randomized controlled trial, it is not an approved drug, and regulators have flagged safety-data gaps. A recent sports-medicine primer places BPC-157 in exactly that cautious frame: unapproved status, regulatory and anti-doping concerns, physician wariness⁸. This maps cleanly onto how Huberman has framed his own past use — injury-related, in the past, and something he explicitly said could have been placebo. That concession is the tell of an honest anecdote, and it is the right prior for a molecule with animal-only efficacy evidence.

Sermorelin: the deep-sleep rationale is contested

Sermorelin is a GHRH analog — the 1–29 fragment of growth-hormone-releasing hormone — and it sits in the broader family we cover in our growth-hormone secretagogues guide and the tesamorelin/GHRH research guide. The popular rationale for taking it is that boosting the GHRH axis deepens slow-wave sleep. In humans, that link is contested. A controlled human study infused a GHRH-receptor antagonist into young men, suppressed growth-hormone secretion by roughly 93%, and found no reduction in slow-wave sleep — evidence that endogenous GHRH is not required for it¹⁰. A second human study argued directly against a growth-hormone-secretagogue role in slow-wave sleep regulation¹¹.

Huberman’s own account fits the uncertainty rather than resolving it: he has said he discontinued sermorelin over a trade-off, where a shift toward deep sleep came at the expense of REM. In other words, by his own telling the personal outcome was net-negative for him. So the mechanism is disputed in the literature and the anecdote landed on “stopped.” There is also a hard regulatory flag here that applies to anyone in tested sport: GHRH and its analogs, sermorelin included, are prohibited at all times under WADA Section S2¹³, and analytical detection methods for this class exist and are in use¹². The same S2 flag applies to MK-677 (ibutamoren) if it comes up in these discussions.

All efficacy rows describe in-vitro, animal, or contested human findings from the cited literature. None of these compounds is an approved medicine for the uses discussed; this table is a literature summary, not a use or dosing guide.

An honest read of the evidence

The single biggest weakness runs through the pinealon and epithalon story: it is a single-lineage literature. Every substantive pinealon, EDR and epithalon paper traces back to Vladimir Khavinson and collaborators at the St. Petersburg Institute of Bioregulation and Gerontology¹²³, and the epithalon primate work sits in the same lineage¹⁴. Findings have not been independently replicated by unaffiliated Western labs, and much of the corpus appears in low-impact or specialist gerontology journals, including one that has since been discontinued⁶. When a whole evidence base flows from one program, the correct scientific posture is caution, not confirmation.

Second, for pinealon specifically there is no human randomized controlled trial on sleep or REM at all. Statements about memory improvement “in elderly patients” appear asserted in reviews without an accessible controlled-trial citation². Huberman’s REM benefit is an uncontrolled personal n=1 with a self-acknowledged possibility of carry-over or placebo — it is an anecdote, and should be read as one. Third, the mechanism data are almost entirely in vitro (cerebellar granule cells, PC12, HeLa) or in non-sleep animal models¹⁵; there is no published human pharmacokinetic or CNS-penetration data, so the proposed “binds DNA in neurons to raise REM” chain is unproven at the whole-organism level.

For BPC-157, efficacy is animal-and-cell only, backed by three small human pilots and no efficacy RCT; it is unapproved and carries flagged safety-data gaps⁷⁸. Even Huberman conceded his outcome might have been placebo. For sermorelin, the deep-sleep rationale is actively contradicted by two human studies¹⁰¹¹, and his personal experience ended in discontinuation. The one internet claim worth debunking plainly is not “pinealon exists” — it does, and it is a real Khavinson tripeptide, so calling it a fabrication would be wrong. The genuine overclaims are the “nightly pinealon protocol,” “Semax for focus,” and “ipamorelin as a top pick at a specific microgram dose.” Those are the parts that were invented around the anecdote, not the peptide itself.

All materials supplied by Condor Research are Research Use Only (RUO). Everything above is in-vitro, animal, and literature findings plus fair-comment on public statements — not a dosing protocol, clinical guidance, or a safety assessment for any organism, and not an endorsement of use by any person. Nothing here concerns human or veterinary use.

Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com